Compare TRMK & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRMK | PGEN |
|---|---|---|
| Founded | 1889 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.2B |
| IPO Year | 1994 | 2013 |
| Metric | TRMK | PGEN |
|---|---|---|
| Price | $46.18 | $7.42 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $44.50 | $8.33 |
| AVG Volume (30 Days) | 317.9K | ★ 6.1M |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | ★ 1.93 | N/A |
| EPS | ★ 2.03 | 0.03 |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | $9.82 | $1,115.92 |
| Revenue Next Year | $4.86 | $81.04 |
| P/E Ratio | ★ $22.71 | $242.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.33 | $2.99 |
| 52 Week High | $49.00 | $7.55 |
| Indicator | TRMK | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 41.47 | 67.89 |
| Support Level | $45.10 | $3.96 |
| Resistance Level | $46.34 | N/A |
| Average True Range (ATR) | 0.68 | 0.40 |
| MACD | -0.26 | 0.03 |
| Stochastic Oscillator | 18.48 | 95.38 |
Trustmark Corp is a bank holding company. Through its subsidiaries, the company operates as a financial services organization providing banking and other financial solutions in Alabama, Florida, Mississippi, Tennessee, and Texas. Its principal products and services include Commercial Banking, Consumer Banking, Mortgage Banking, Insurance, Wealth Management and Trust Services, and others. The company is managed along two operating segments: General Banking and Wealth Management. The General Banking segment, which generates the majority of the revenue, provides all traditional banking products and services, including loan deposits, and also consists of internal operations.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.